Page last updated: 2024-11-13

1-(4-(3-bromophenoxy)butyl)-1h-imidazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

The compound 1-(4-(3-bromophenoxy)butyl)-1H-imidazole is a relatively obscure chemical and its significance, if any, for research is not widely documented.

Here's why it's difficult to provide specific information:

* **Lack of common name:** The provided name is a systematic IUPAC name, not a common name or abbreviation. This makes it harder to find information about it in scientific literature.
* **Limited information:** There is no clear indication of its use or research applications. It may be a synthetic intermediate, a potential drug candidate, or a component of a specific research project.
* **Specificity:** The structure suggests it could be a compound with potential biological activity, but without further context, it's difficult to say for sure.

**Here's how you can potentially find more information:**

* **Consult scientific databases:** Try searching for the IUPAC name in databases like PubChem, SciFinder, or Reaxys. These databases often provide chemical properties and potential applications.
* **Look for patents or publications:** Search for patents or research articles that mention the specific compound or closely related structures. This might reveal information about its synthesis, biological activity, or potential applications.
* **Contact experts:** If you have access to relevant scientific communities or research groups, you could ask experts in the field for insights into the compound's potential significance.

**In summary, without more context or research on the specific compound, it's difficult to determine its importance for research.**

1-(4-(3-bromophenoxy)butyl)-1H-imidazole: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID44586265
CHEMBL ID482686
MeSH IDM0582573

Synonyms (5)

Synonym
1-(4-(3-bromophenoxy)butyl)-1h-imidazole
bdbm50271549
CHEMBL482686 ,
nsc-824668
nsc824668
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Heme oxygenase 2Rattus norvegicus (Norway rat)IC50 (µMol)2.20001.10004.483310.0000AID1633152; AID764734
Nitric oxide synthase, brainHomo sapiens (human)Ki60.00000.01501.18117.3000AID404423
Heme oxygenase 2Homo sapiens (human)IC50 (µMol)2.20002.20004.92007.6400AID1633152
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (37)

Processvia Protein(s)Taxonomy
response to hypoxiaNitric oxide synthase, brainHomo sapiens (human)
regulation of sodium ion transportNitric oxide synthase, brainHomo sapiens (human)
arginine catabolic processNitric oxide synthase, brainHomo sapiens (human)
nitric oxide biosynthetic processNitric oxide synthase, brainHomo sapiens (human)
striated muscle contractionNitric oxide synthase, brainHomo sapiens (human)
myoblast fusionNitric oxide synthase, brainHomo sapiens (human)
response to heatNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transport into cytosolNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingNitric oxide synthase, brainHomo sapiens (human)
peptidyl-cysteine S-nitrosylationNitric oxide synthase, brainHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationNitric oxide synthase, brainHomo sapiens (human)
multicellular organismal response to stressNitric oxide synthase, brainHomo sapiens (human)
xenobiotic catabolic processNitric oxide synthase, brainHomo sapiens (human)
vasodilationNitric oxide synthase, brainHomo sapiens (human)
negative regulation of potassium ion transportNitric oxide synthase, brainHomo sapiens (human)
cell redox homeostasisNitric oxide synthase, brainHomo sapiens (human)
positive regulation of DNA-templated transcriptionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IINitric oxide synthase, brainHomo sapiens (human)
negative regulation of hydrolase activityNitric oxide synthase, brainHomo sapiens (human)
negative regulation of serotonin uptakeNitric oxide synthase, brainHomo sapiens (human)
negative regulation of calcium ion transportNitric oxide synthase, brainHomo sapiens (human)
regulation of cardiac muscle contractionNitric oxide synthase, brainHomo sapiens (human)
regulation of ryanodine-sensitive calcium-release channel activityNitric oxide synthase, brainHomo sapiens (human)
cellular response to growth factor stimulusNitric oxide synthase, brainHomo sapiens (human)
positive regulation of the force of heart contractionNitric oxide synthase, brainHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayNitric oxide synthase, brainHomo sapiens (human)
positive regulation of sodium ion transmembrane transportNitric oxide synthase, brainHomo sapiens (human)
regulation of calcium ion transmembrane transport via high voltage-gated calcium channelNitric oxide synthase, brainHomo sapiens (human)
positive regulation of membrane repolarization during ventricular cardiac muscle cell action potentialNitric oxide synthase, brainHomo sapiens (human)
positive regulation of guanylate cyclase activityNitric oxide synthase, brainHomo sapiens (human)
nitric oxide mediated signal transductionNitric oxide synthase, brainHomo sapiens (human)
response to hormoneNitric oxide synthase, brainHomo sapiens (human)
negative regulation of blood pressureNitric oxide synthase, brainHomo sapiens (human)
response to lipopolysaccharideNitric oxide synthase, brainHomo sapiens (human)
response to hypoxiaHeme oxygenase 2Homo sapiens (human)
response to oxidative stressHeme oxygenase 2Homo sapiens (human)
heme catabolic processHeme oxygenase 2Homo sapiens (human)
heme oxidationHeme oxygenase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
nitric-oxide synthase activityNitric oxide synthase, brainHomo sapiens (human)
calcium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
protein bindingNitric oxide synthase, brainHomo sapiens (human)
calmodulin bindingNitric oxide synthase, brainHomo sapiens (human)
FMN bindingNitric oxide synthase, brainHomo sapiens (human)
sodium channel regulator activityNitric oxide synthase, brainHomo sapiens (human)
heme bindingNitric oxide synthase, brainHomo sapiens (human)
tetrahydrobiopterin bindingNitric oxide synthase, brainHomo sapiens (human)
arginine bindingNitric oxide synthase, brainHomo sapiens (human)
transmembrane transporter bindingNitric oxide synthase, brainHomo sapiens (human)
cadmium ion bindingNitric oxide synthase, brainHomo sapiens (human)
calcium-dependent protein bindingNitric oxide synthase, brainHomo sapiens (human)
flavin adenine dinucleotide bindingNitric oxide synthase, brainHomo sapiens (human)
NADP bindingNitric oxide synthase, brainHomo sapiens (human)
scaffold protein bindingNitric oxide synthase, brainHomo sapiens (human)
heme oxygenase (decyclizing) activityHeme oxygenase 2Homo sapiens (human)
protein bindingHeme oxygenase 2Homo sapiens (human)
metal ion bindingHeme oxygenase 2Homo sapiens (human)
heme bindingHeme oxygenase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (20)

Processvia Protein(s)Taxonomy
photoreceptor inner segmentNitric oxide synthase, brainHomo sapiens (human)
nucleoplasmNitric oxide synthase, brainHomo sapiens (human)
cytoplasmNitric oxide synthase, brainHomo sapiens (human)
mitochondrionNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
cytoskeletonNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
sarcoplasmic reticulumNitric oxide synthase, brainHomo sapiens (human)
sarcolemmaNitric oxide synthase, brainHomo sapiens (human)
dendritic spineNitric oxide synthase, brainHomo sapiens (human)
membrane raftNitric oxide synthase, brainHomo sapiens (human)
synapseNitric oxide synthase, brainHomo sapiens (human)
perinuclear region of cytoplasmNitric oxide synthase, brainHomo sapiens (human)
cell peripheryNitric oxide synthase, brainHomo sapiens (human)
protein-containing complexNitric oxide synthase, brainHomo sapiens (human)
plasma membraneNitric oxide synthase, brainHomo sapiens (human)
postsynaptic densityNitric oxide synthase, brainHomo sapiens (human)
cytosolNitric oxide synthase, brainHomo sapiens (human)
nucleusNitric oxide synthase, brainHomo sapiens (human)
endoplasmic reticulum membraneHeme oxygenase 2Homo sapiens (human)
plasma membraneHeme oxygenase 2Homo sapiens (human)
membraneHeme oxygenase 2Homo sapiens (human)
specific granule membraneHeme oxygenase 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID1202421Selectivity index, ratio of IC50 for MDCK cells to IC50 human DU145 cells2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID764724Reduction of HO-2 mRNA expression in human imatinib mesylate-resistant LAMA-84 cells at 10 uM by RT-PCR analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1422094Cytotoxicity against human K562R cells assessed as decrease in cell viability after 24 hrs by XTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
AID1202416Cytotoxicity against human PC3 cells incubated for 72 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID1202413Cytotoxicity against human MDA-MB-231 cells incubated for 72 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID764720Potentiation of imatinib mesylate-induced ROS production in human imatinib mesylate-resistant LAMA-84 cells at 10 uM by spectrofluorometric analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1202420Selectivity index, ratio of IC50 for MDCK cells to IC50 human MCF7 cells2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID1202415Cytotoxicity against human DU145 cells incubated for 72 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID764722Induction of apoptosis in human imatinib mesylate-resistant LAMA-84 cells at 10 uM after 3 hrs using propidium iodide staining by FACS analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1422093Inhibition of heme oxygenase 1 in Sprague-Dawley rat spleen microsomal fraction assessed as decrease in bilirubin formation using biliverdin reductase as substrate after 60 mins by spectrophotometric method2018European journal of medicinal chemistry, Oct-05, Volume: 158Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
AID1422092Cytotoxicity against imatinib-sensitive human K562 cells assessed as decrease in cell viability after 24 hrs by XTT assay2018European journal of medicinal chemistry, Oct-05, Volume: 158Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
AID1633157Inhibition of HO-1 in Sprague-Dawley rat spleen microsomes using NADPH as substrate incubated for 60 mins by spectrometry based assay2019European journal of medicinal chemistry, Apr-01, Volume: 167Progress in the development of selective heme oxygenase-1 inhibitors and their potential therapeutic application.
AID1202423Selectivity index, ratio of IC50 for MDCK cells to IC50 human LNCAP cells2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID1202419Selectivity index, ratio of IC50 for MDCK cells to IC50 human MDA-MB-231 cells2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID764727Cell cycle arrest in human imatinib mesylate-resistant LAMA-84 cells assessed as accumulation at S and G2/M phase at 10 uM after 3 hrs by FACS analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID764732Inhibition of HO-1 (unknown origin) expressed in human imatinib mesylate-resistant LAMA-84 cells assessed as bilirubin formation at 10 uM after 24 hrs relative to control2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID764721Potentiation of imatinib mesylate-induced apoptosis in human imatinib mesylate-resistant LAMA-84 cells at 10 uM after 3 hrs using propidium iodide staining by FACS analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1202422Selectivity index, ratio of IC50 for MDCK cells to IC50 human PC3 cells2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID1202418Cytotoxicity against MDCK cells incubated for 72 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID1633152Inhibition of HO-2 (unknown origin)2019European journal of medicinal chemistry, Apr-01, Volume: 167Progress in the development of selective heme oxygenase-1 inhibitors and their potential therapeutic application.
AID764729Potentiation of imatinib mesylate-induced cytotoxicity in human imatinib mesylate-resistant LAMA-84 cells assessed as reduction of cell survival at 10 uM after 20 mins by ATP-lite1step assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID764730Cytotoxicity against human imatinib mesylate-resistant LAMA-84 cells assessed as reduction of cell survival at 10 uM after 20 mins by ATP-lite1step assay2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1202417Cytotoxicity against human LNCAP cells incubated for 72 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
AID764735Inhibition of Sprague-Dawley rat spleen microsomal HO-1 assessed as bilirubin formation after 60 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID404423Inhibition of nNOS assessed as conversion of L-[3H]arginine to L-[3H]citrulline2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase.
AID1422106Induction of ROS production in human K562R cells at 10 uM by DCFH-DA dye based spectrofluorometric method2018European journal of medicinal chemistry, Oct-05, Volume: 158Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
AID764734Inhibition of Sprague-Dawley rat brain HO-2 assessed as bilirubin formation after 60 mins by spectrophotometric analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1422103Inhibition of heme oxygenase 1 in human K562R cell lysates assessed as decrease in bilirubin formation at 10 uM after 60 mins by spectrophotometric method2018European journal of medicinal chemistry, Oct-05, Volume: 158Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines.
AID764726Potentiation of imatinib mesylate-induced cell cycle arrest in human imatinib mesylate-resistant LAMA-84 cells assessed as accumulation at S and G2/M phase at 10 uM after 3 hrs by FACS analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID764725Reduction of HO-1 mRNA expression in human imatinib mesylate-resistant LAMA-84 cells at 10 uM by RT-PCR analysis2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
Evaluation of novel aryloxyalkyl derivatives of imidazole and 1,2,4-triazole as heme oxygenase-1 (HO-1) inhibitors and their antitumor properties.
AID1202414Cytotoxicity against human MCF7 cells incubated for 72 hrs by sulforhodamine B assay2015European journal of medicinal chemistry, , Volume: 96Novel imidazole derivatives as heme oxygenase-1 (HO-1) and heme oxygenase-2 (HO-2) inhibitors and their cytotoxic activity in human-derived cancer cell lines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.26 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index5.21 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]